Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Editorial

Accepted on 30 Jun 2025

Editorial: Safety consideration in the development of anti-tumor monoclonal antibodies during drug development

in Pharmacology of Anti-Cancer Drugs

Tao Wang
Shaad Essa Abedin
Jan Willem Van Der Laan

Frontiers in Oncology

doi 10.3389/fonc.2025.1640377

157 views

Original Research

Accepted on 30 Jun 2025

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: A Pharmacovigilance study using the FAERS and JADER

in Pharmacology of Anti-Cancer Drugs

Xiaomeng Di
Xiaohong Shi
Feng Gai
Jiawei Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1621045

Review

Accepted on 30 Jun 2025

M6A RNA Modification: Focusing on Non-small Cell Lung Cancer Progression, Therapeutic Strategies and Challenges

in Pharmacology of Anti-Cancer Drugs

Yuyang Yan
Jiarui Yin
Quan Ding
Yan Lu
Shuhua Gou
Xi Xu
Yulin Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1622359

104 views

Original Research

Accepted on 25 Jun 2025

Utilization of Dexrazoxane in Patients Treated with Doxorubicin: A Retrospective, Propensity Matched Analysis of Cardiac Function and Toxicity

in Pharmacology of Anti-Cancer Drugs

Zachary Neiman
Carlo Legasto
Alan Chin
Tiffany Guan
Brian Schulte

Frontiers in Oncology

doi 10.3389/fonc.2025.1621409

Original Research

Accepted on 23 Jun 2025

Cell-in-Cell Associated lncRNA Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer

in Pharmacology of Anti-Cancer Drugs

Junzuo Lin
Liancheng Wu
Zhengfei Zhao

Frontiers in Oncology

doi 10.3389/fonc.2025.1597187

163 views

Systematic Review

Accepted on 23 Jun 2025

A bibliometric and visual analysis of Jak1 to explore trends and frontiers

in Pharmacology of Anti-Cancer Drugs

聪俞
xiaodon xie
jiaming cao
wenguang chen
ensi hon

Frontiers in Oncology

doi 10.3389/fonc.2025.1537508

Original Research

Published on 18 Jun 2025

The anti-inflammatory effects of oridonin in resisting esophageal cancer

in Pharmacology of Anti-Cancer Drugs

Mengfan Peng
Xiaofang Zhang
Lei Yang
Baosong Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1585057

298 views

Review

Published on 18 Jun 2025

Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance

in Pharmacology of Anti-Cancer Drugs

Hongtao Zhang
Zhaoming Yang
Zhengwu Jiang
Zhijian Zhao
Xun Chen
Jian Wan
Yukun Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1595195

318 views

Original Research

Published on 12 Jun 2025

Synergistic effects of 5-fluorouracil in combination with salinomycin promoted ferroptosis via inhibiting SLC7A11/GPX4 in colorectal cancer

in Pharmacology of Anti-Cancer Drugs

Can Wang
Junyang Wang
Fei Xing
Ning Liu
Xudong Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1558290

810 views

Clinical Trial

Published on 10 Jun 2025

Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review

in Pharmacology of Anti-Cancer Drugs

Rick Fontenot
Neha Biyani
Kishor Bhatia
Reggie Ewesuedo
Marc Chamberlain
Panna Sharma

Frontiers in Oncology

doi 10.3389/fonc.2025.1577468

925 views

Original Research

Published on 06 Jun 2025

Interrogation of macrophage-related prognostic signatures reveals a potential immune-mediated therapy strategy by histone deacetylase inhibition in glioma

in Pharmacology of Anti-Cancer Drugs

Xisen Wang
Xuya Wang
Lei Chen
Haozhe Ding
Jikang Fan
Jianshen Liang
Yu Zhang
Yiming Li
Yiming Zhang
Shengping Yu

Frontiers in Oncology

doi 10.3389/fonc.2025.1554845

1,298 views

Original Research

Published on 29 May 2025

A study on the effectiveness and safety of interventional embolization using drug-loaded microspheres in combination with sorafenib and envafolimab for intermediate and advanced renal cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Cheng Chen
Yanfeng Shen
Yanhong Ma
Yingying Zhang
Shuyan Zhang
Na Su
Hefei Guo
Yapeng Guo
Xuehui Zhang
Xianming Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1558410

722 views

Correction

Published on 29 May 2025

Corrigendum: LCT-3d induces oxidative stress-mediated apoptosis by upregulating death receptor 5 in gastric cancer cells

in Pharmacology of Anti-Cancer Drugs

Menglin Wang
Xinxin Wu
Lu Yu
Zi-yun Hu
Xiaobo Li
Xia Meng
Chun-tao Lv
Gi-Young Kim
Yung Hyun Choi
Zhenya Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1590809

495 views

Original Research

Published on 29 May 2025

Molecular targets and mechanisms of cortex mori for lung cancer treatment: a network pharmacology study, molecular docking and in vitro and in vivo experimental validation

in Pharmacology of Anti-Cancer Drugs

Ying-Ying Shao
Qiu-Hong Yang
Shu-Fen He
Han-Bin Zhang
Wei-Chao Han
Bao-Cheng Xie
Rui-Rong He
Wen-Xin Hong

Frontiers in Oncology

doi 10.3389/fonc.2025.1587856

1,575 views

Original Research

Published on 29 May 2025

Development of CSOARG: a single-cell and multi-omics-based machine learning model for ovarian cancer prognosis and drug response prediction

in Pharmacology of Anti-Cancer Drugs

Junyu Chen
Bin Guan
Jihong Zhang
Xin Li
Jingyi Fang
Wencai Guan
Qi Lu
Guoxiong Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1592426

961 views

Brief Research Report

Published on 27 May 2025

Severe immunotherapy-related thrombocytopenia in metastatic bone cancer: a multicenter retrospective case series highlighting early recognition and management

in Pharmacology of Anti-Cancer Drugs

Qian Gao
Zhaonong Yao
Yuhong Yao
Yunxia Liu
Jianshui Mao
Binghao Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1574379

942 views